Nrx pharmaceuticals announces initiation of emergency use training and extension of phase 2/3 inhaled zyesami™ (aviptadil-acetate) trial in the nation of georgia

Radnor, pa., july 6, 2021 /prnewswire/ -- nrx pharmaceuticals (nasdaq: nrxp) (nrx), a clinical stage biopharmaceutical company, today announced it is initiating clinical training of nation of georgia (georgia) icu physicians, in the use of intravenous zyesami™ (aviptadil- acetate) for emergency use in patients suffering with critical covid-19, and inhaled zyesami™ for use in phase 2/3 clinical trials, for patients suffering with covid-19.
NRXP Ratings Summary
NRXP Quant Ranking